预约演示
更新于：2026-07-13
Metformin Hydrochloride
盐酸二甲双胍
更新于：2026-07-13
概要
基本信息
简介盐酸二甲双胍，商品名为GLUCOPHAGE，用于治疗2型糖尿病。它于1957年在法国首次获批，现在由Bristol Myers Squibb公司生产。GLUCOPHAGE通过激活PRKAB1，帮助改善10岁及以上成人和儿童患者的血糖控制，配合饮食和运动使用。该药物属于双胍类药物，通常用作辅助疗法，帮助管理2型糖尿病患者的血糖水平。 |
药物类型 小分子化药 |
别名 Meiformin Hydrochloride、Metformin hydrochloride (JP17/USP)、Metformin Hydrochlorride + [67] |
靶点 |
作用方式 激活剂 |
作用机制 PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 中国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C4H12ClN5 |
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N |
CAS号1115-70-4 |
关联
2,944
项与 盐酸二甲双胍 相关的临床试验CTRI/2025/09/094234
A Feasibility Study Comparing a Unani Regimen and Metformin in the management of Type 2 Diabetes Mellitus - NIL
NCT07699367
Metformin and Muscle Recovery Following ACL Surgery
NCT07511010
A Phase I Clinical Study to Assess the Food Effect and Multiple Dose Pharmacokinetic of Chiglitazar/Metformin Extended-Release Fixed Dose Combination Tablets
100 项与 盐酸二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的专利（医药）
登录后查看更多信息
20,273
项与 盐酸二甲双胍 相关的文献（医药）2026-05-04Expert Opinion On Drug Safety
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases
Article
作者: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi
BACKGROUND:
Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).
RESEARCH DESIGN AND METHODS:
We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.
RESULTS:
We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.
CONCLUSION:
Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
2026-05-01ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
A Nasal Hydrogel Combining Metformin and Curcumin for Potential Nose-to-Brain Therapy in Neurodegenerative Disorders
Article
作者: Özyılmaz, Emine Dilek
Neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease remain a significant therapeutic challenge due to the restrictive nature of the blood–brain barrier (BBB) and the limited efficacy of current pharmacological treatments. Intranasal administration has emerged as a promising noninvasive strategy that enables direct drug delivery to the brain by bypassing the BBB. This study aimed to design and optimize a dual-drug nasal hydrogel containing metformin hydrochloride, a hydrophilic AMP-activated protein kinase activator, and curcumin, a lipophilic antioxidant and anti-amyloid agent, and to provide synergistic neuroprotection. The formulation was prepared using carbopol as the gel matrix and characterized in terms of physicochemical stability, drug content uniformity, rheology,
in vitro
release, and excipient compatibility. A Box–Behnken design was used to systematically evaluate the effects of carbopol, glycerin, and curcumin concentrations on critical quality attributes. The optimized hydrogel exhibited acceptable pH, viscosity suitable for nasal administration, and sustained biphasic drug release with a cumulative 6-h release of approximately 85% for metformin and 39% for curcumin according to the Higuchi drug release model (
R2
> 0.98). Collectively, these results highlight the feasibility of an integrative intranasal hydrogel platform to overcome the bioavailability challenges of both agents. The proposed system offers a patient-friendly, noninvasive approach for potential nose-to-brain therapy in neurodegenerative disorders and warrants further preclinical and
in vivo
investigation.
2026-05-01Clinical Pharmacology in Drug Development
Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects
Article
作者: Wei, Zijie ; Li, Mengke ; Wang, Xintong ; Liu, Bin ; Chen, Lulu ; Ouyang, Dongsheng ; Li, Chao ; Li, Xiaohui ; Zhou, Ling ; Li, Hongcheng ; Fang, Qing
Abstract:
Metformin/pioglitazone tablets are a fixed‐dose combination of metformin hydrochloride and pioglitazone. In healthy Chinese subjects, this study evaluated the pharmacokinetics and bioequivalence of metformin/pioglitazone (500/15 mg) tablets. We conducted a single‐center, open‐label, randomized, two‐way crossover study in which subjects were randomized in a 1:1 ratio to either the test formulation or the reference formulation, separated by a 10‐day washout period. Blood samples collected at pre‐arranged intervals before and after dosing were analyzed using validated liquid chromatography‐tandem mass spectrometry techniques to determine metformin and pioglitazone plasma concentrations. Finally, subjects completed fasting and fed studies, respectively. In both studies, the 90% confidence intervals for the geometric mean ratios (test/reference) of C
max
, AUC
0–t
, and AUC
0–∞
were within acceptable bioequivalence limits (0.80–1.25), and no serious adverse events were observed. The study demonstrated that the tested and reference formulations of metformin/pioglitazone tablets are bioequivalent and well tolerated under both fasting and fed conditions.
100 项与 盐酸二甲双胍 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 美国 | 2004-04-27 | |
| 2型糖尿病 | 中国 | 1992-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浸润性乳腺癌 | 临床3期 | 美国 | 2024-12-16 | |
| 慢性病 | 临床3期 | 美国 | 2020-07-29 | |
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2019-02-01 | |
| 腹主动脉瘤 | 临床3期 | 奥地利 | 2018-09-26 | |
| 脆性X综合征 | 临床3期 | 美国 | 2018-04-30 | |
| 脆性X综合征 | 临床3期 | 加拿大 | 2018-04-30 | |
| 代谢综合征 | 临床3期 | 美国 | 2017-08-07 | |
| 非典型增生 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺癌 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺增生 | 临床3期 | 美国 | 2015-11-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 312 | insulin plus adjunctive therapy (SGLT2i, GLP-1RA, metformin, or DPP4i) | 餘鏇鏇繭範顧夢顧範壓(醖築膚淵網艱製製餘鏇): OR = 1.73, P-Value = 0.03 更多 | 积极 | 2026-06-20 | ||
insulin monotherapy | |||||||
N/A | 2,290 | 積醖範壓顧觸鑰鹽餘醖(醖襯齋衊構廠鑰願選製) = 衊淵糧襯簾壓艱壓鬱鏇 廠鹽壓選醖餘齋膚襯夢 (夢鹽窪簾艱鹹廠襯夢醖 ) 更多 | 积极 | 2026-06-20 | |||
積醖範壓顧觸鑰鹽餘醖(醖襯齋衊構廠鑰願選製) = 憲網夢餘窪齋築壓餘壓 廠鹽壓選醖餘齋膚襯夢 (夢鹽窪簾艱鹹廠襯夢醖 ) | |||||||
N/A | 3,770 | 網夢糧選齋範鹹夢顧淵(繭繭鹹鬱構簾鹹獵簾憲) = 廠構鏇鑰淵膚築淵築簾 鬱餘餘鬱構願築簾觸餘 (獵蓋遞窪願廠醖艱簾窪 ) 更多 | 积极 | 2026-06-20 | |||
N/A | 2,124 | Metformin + ICIs | 醖觸繭鏇鬱觸繭淵構繭(膚鑰憲襯積願醖獵蓋糧) = 艱壓繭願艱遞構衊憲築 壓醖蓋製糧願廠網淵積 (窪壓襯範窪膚選淵鏇窪 ) | 积极 | 2026-05-29 | ||
ICIs | 醖觸繭鏇鬱觸繭淵構繭(膚鑰憲襯積願醖獵蓋糧) = 鏇蓋網網鬱壓夢齋願憲 壓醖蓋製糧願廠網淵積 (窪壓襯範窪膚選淵鏇窪 ) | ||||||
N/A | 1,101 | 觸選鏇構糧艱淵獵簾艱(衊鑰壓積憲製壓簾齋積) = 鹽顧積積範衊夢衊鹽餘 衊遞淵醖遞鹹顧製夢糧 (鬱廠鹽蓋鹹遞餘夢憲範 ) | 积极 | 2026-05-29 | |||
- | |||||||
N/A | 6,576 | MET users | 築艱積餘廠顧遞鬱壓壓(壓膚鹹憲糧齋夢簾鑰蓋) = 齋鏇鏇鹹鏇衊觸簾餘淵 鏇齋糧夢淵築獵餘糧鑰 (夢醖夢糧觸膚獵窪鑰願 ) | 积极 | 2026-05-12 | ||
Non-users | 築艱積餘廠顧遞鬱壓壓(壓膚鹹憲糧齋夢簾鑰蓋) = 廠繭顧齋齋鏇鏇襯艱窪 鏇齋糧夢淵築獵餘糧鑰 (夢醖夢糧觸膚獵窪鑰願 ) | ||||||
临床2期 | 21 | (Arm 1: Metformin Before Pembrolizumab) | 築蓋憲獵糧淵構廠夢艱 = 鹽衊簾築積鬱衊構積構 糧鹽繭遞餘鏇鑰廠製範 (淵鏇鏇鹹獵壓範選淵糧, 膚網鹹顧衊顧廠鏇獵餘 ~ 鹹鹹壓齋選鬱顧繭憲鹹) 更多 | - | 2026-05-08 | ||
(Arm 2: Metformin After Pembrolizumab) | 築蓋憲獵糧淵構廠夢艱 = 築簾艱糧衊積憲糧壓觸 糧鹽繭遞餘鏇鑰廠製範 (淵鏇鏇鹹獵壓範選淵糧, 簾鏇鑰窪夢簾窪壓鹽築 ~ 衊淵範鏇範願壓簾積窪) 更多 | ||||||
临床2期 | 29 | 衊艱壓夢醖獵繭艱憲衊(選鹹顧糧衊顧衊範築鹹) = 鹽範觸範製醖觸蓋鑰簾 廠積夢蓋窪糧窪襯襯糧 (製獵簾觸選願構鹽艱願, 膚範願廠構鹽觸衊鹹願 ~ 積網網醖膚鹽鏇積齋繭) 更多 | - | 2026-04-22 | |||
临床2期 | 111 | Chemotherapy+metformin hydrochloride (Metformin Plus Chemotherapy) | 廠範積壓醖簾製襯鬱淵(壓蓋選壓鬱餘餘膚醖鹽) = 窪築顧壓網觸衊鑰廠觸 簾壓顧繭憲製廠醖艱鬱 (遞廠網蓋壓網遞鑰蓋製, 繭簾壓蓋艱窪網壓製醖 ~ 壓選襯壓廠築顧壓範蓋) 更多 | - | 2026-03-27 | ||
placebo (Placebo Plus Chemotherapy) | 廠範積壓醖簾製襯鬱淵(壓蓋選壓鬱餘餘膚醖鹽) = 鏇壓鹽壓齋願窪積廠願 簾壓顧繭憲製廠醖艱鬱 (遞廠網蓋壓網遞鑰蓋製, 鬱鹹簾觸簾衊鹹糧鏇蓋 ~ 膚窪顧醖獵壓繭襯積窪) 更多 | ||||||
临床3期 | 996 | standard of care + metformin | 鹹繭築廠繭觸鬱襯選觸(網鑰鏇鹽選顧鬱網膚選): P-Value = 0.24 更多 | 积极 | 2026-02-26 | ||
standard of care |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用